Login to Your Account

Nivalis mulls next steps after cavosonstat phase II fail in CF

By Marie Powers
News Editor

Tuesday, November 29, 2016

The management team at Nivalis Therapeutics Inc. didn’t exactly pull the plug on lead candidate cavosonstat after it flunked its first phase II experiment in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. But investors were less forgiving.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription